DocWire News Editors

DocwireNews

A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel (cilta-cel) demonstrated early, deep, and durable responses in patients with relapsed/refractory multiple myeloma that had been heavily pretreated. The study was conducted by Thomas Martin, MD, and colleagues and was presented at the 2021 American Society of Hematology Annual Meeting.The study sought to characterize cilta-cel safety, confirm the recommended phase II dose (from phase Ib), and evaluate cilta-cel efficacy (phase II). Researchers assessed 97 eligible patients with myeloma who received three or more prior therapies; whose disease was refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); and who had received a PI, IMiD, and an anti-CD38 antibody. The study population were administered a single cilta-cel infusion over 5 to 7 days following lymphodepletion.The results show that,&nbsp;as of a data cut-off of February 11, 2021, the population of interest had received a median of six prior lines of therapy. The treatment has demonstrated robust efficacy, with an objective response rate (ORR) of 97.9%. The investigators observed that more than 80% of patients achieved stringent complete response (sCR), and around 95% achieved very good partial response or better. They noted that the median time to first response was 1 month (range = 0.9-10.7), suggesting rapid response. The median time to best response was 2.6 months (range = 0.9-15.2), and the median time to CR or better was also 2.6 months (range = 0.9-15.2).Responses also appeared to be durable, with a median duration of response of 21.8 months, according to the researchers. The 18-month progression-free and overall survival rates were 66% and 80.9%, respectively.In terms of the treatment&rsquo;s safety profile, the most common grade 3/4 hematologic adverse events (AEs; occuring in &ge;25% of patients) were neutropenia (94.8%), anemia (68.0%), leukopenia (60.8%), thrombocytopenia (59.8%), and lymphopenia (49.5%). There were no patient deaths related to cytopenias and no new safety signals.The researchers concluded that, &ldquo;cilta-cel demonstrated a manageable safety profile with no new safety signals observed with longer follow-up. Further investigations of cilta-cel are ongoing in earlier lines of therapy and in outpatient settings.&rdquo;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Updated Results from CARTITUDE-1 Trial Show Continued Efficacy of Ciltacabtagene Autoleucel in Treating Relapsed/Refractory Multiple Myeloma

ASH Annual Meeting and Exposition 2021

A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel (cilta-cel) demonstrated early, deep, and durable responses ...

Updated Results from CARTITUDE-1 Trial Show Continued Efficacy of Ciltacabtagene Autoleucel in

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe